BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/4/2014 5:33:00 PM | Browse: 331 | Download: 256
Publication Name World Journal of Gastroenterology
Manuscript ID 4404
Country of Manuscript Source South Korea
2013-06-29 09:22
Peer-Review Started
2013-07-01 15:03
To Make the First Decision
2013-09-02 16:03
Return for Revision
2013-09-03 21:36
2013-09-30 10:50
Second Decision
2013-10-21 17:34
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-10-22 07:30
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-01-06 10:27
Publish the Manuscript Online
2014-01-20 17:10
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Autobiography
Article Title Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Ji Eun Lee, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Young Kyoung You and Myung Ah Lee
Funding Agency and Grant Number
Correspondence To Myung Ah Lee, MD, PhD, Department of Internal Medicine, Hepato-Biliary-Pancreatic Cancer Center, Cancer Research Institute, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 137-040, South Korea. angelamd@catholic.ac.kr
Keywords Hepatocellular carcinoma; Sorafenib; Epirubicin; Cisplatin; 5-FU
Core Tip For advanced and metastatic hepatocellular carcinoma (HCC), sorafenib has been used as the standard systemic treatment. However, after failure to treat with sorafenib, no effective therapy is available. In the present study, we suggested that cytotoxic combination chemotherapy might be the another option for the treatment of progressive HCC. The patients with the age over 60 and a stable primary liver mass were benefit from the chemotherapy, leading to survival prolongation. Most clinical trials are currently focused on target agent because HCC is considered to be chemo-resistant cancer. Based on our data, new clinical trials using chemotherapy should be tried beyond sorafenib.
Publish Date 2014-01-20 17:10
Citation Lee JE, Bae SH, Choi JY, Yoon SK, You YK, Lee MA. Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J Gastroenterol 2014; 20(1): 235-241
Url http://www.wjgnet.com/1007-9327/full/v20/i1/235.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i1.235
Full Article (PDF) WJG-20-235.pdf
Full Article (Word) WJG-20-235.doc
Revised Manuscript 4404-Review.docx
Peer-review Report 4404-Peer review(s).pdf
Answering Reviewers 4404-Answering reviewers.pdf
Scientific Editor Work List 4404-Scientific editor work list.doc
Copyright License Agreement 4404-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 4404-Language certificate.pdf